<- Go Home
Guard Therapeutics International AB (publ)
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Market Cap
SEK 27.4M
Volume
21.4K
Cash and Equivalents
SEK 69.8M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
SEK 34.80
52 Week Low
SEK 1.10
Dividend
N/A
Price / Book Value
0.49
Price / Earnings
-0.18
Price / Tangible Book Value
0.49
Enterprise Value
-SEK 42.3M
Enterprise Value / EBITDA
N/A
Operating Income
-SEK 118.6M
Return on Equity
199.26%
Return on Assets
-101.28
Cash and Short Term Investments
SEK 69.8M
Debt
N/A
Equity
SEK 55.6M
Revenue
N/A
Unlevered FCF
-SEK 59.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium